参考文献/References:
［1］BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries ［J］. CA-A Cancer Journal for Clinicians, 2018, 68(6): 394-424.
［2］CHEN Wanqing, ZHENG Rongshou, BAADE P D, et al. Cancer statistics in China, 2015 ［J］. CA-A Cancer Journal for Clinicians, 2016, 66(2): 115-132.
［3］NOONE A H, KRAPCHO M E. SEER cancer statistics review ［Z］, 2018: 1975-2015.
［4］ALLEMANI C, MATSUDA T, DI CARLO V, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37，513，025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries ［J］. Lancet, 2018, 391(1125): 1023-1075.
［5］BURGER R A, BRADY M F, BOOKMAN M A, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer ［J］. The New England Journal of Medicine, 2011, 365(26): 2473-2483.
［6］PERREN T J, SWART A M, PFISTERER J, et al. A phase 3 trial of bevacizumab in ovarian cancer ［J］. The New England Journal of Medicine, 2011, 365(26): 2484-2496.
［7］Burger RA ED, Tewari KS ea. Final overall survival (OS) analysis of an international randomized tria evaluating bevacizumab (BEV) in th primary treatment of advanced ovarian primary treatment of advanced ovarianel cancer: an NRG Oncology/Gynecologic Oncology Group (GOG) study，2018，36(15 suppl): 5517.
［8］OZA A M, SELLE F, DAVIDENKO I, et al. Efficacy and safety of Bevacizumab-Containing therapy in newly diagnosed ovarian cancer ROSiA Single-Arm phase 3B study ［J］. International Journal of Gynecological Cancer, 2017, 27(1): 50-58.
［9］Pignata S LD, Joly F ea. Chemotherapy plus or minus bevacizumab for platinum-sensitive ovarian cancer patients recurring after a bevacizumab containing first line treatment: the randomized phase 3 tria MITO16B-MaNGO OV2B-ENGOT OV17 ［J］. Journal of Clinical Oncology,2018，36(15): 5506.
［10］AGHAJANIAN C, BLANK S V, GOFF B A, et al. OCEANS: A randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with Platinum-Sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer ［J］. Journal of Clinical Oncology, 2012, 30(17): 2039-2045.
［11］COLEMAN R L, BRADY M F, HERZOG T J, et al. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial ［J］. Lancet Oncology, 2017, 18(6): 779-791.
［12］WALSH C S. Two decades beyond BRCA1/2: Homologous recombination, hereditary cancer risk and a target for ovarian cancer therapy ［J］. Gynecologic Oncology, 2015, 137(2): 343-350.
［13］PENNINGTON K P, WALSH T, HARRELL M I, et al. Germline and somatic mutations in homologous recombination genes predict Platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas ［J］. Clinical Cancer Research, 2014, 20(3): 764-775.
［14］LEDERMANN J, HARTER P, GOURLEY C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer ［J］. The New England Journal of Medicine, 2012, 366(15): 1382-1392.
［15］PUJADE-LAURAINE E, LEDERMANN J A, SELLE F A, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial ［J］. Lancet Oncology, 2017, 18(9): 1274-1284.
［16］MIRZA M R, MONK B J, HERRSTEDT J, et al. Niraparib maintenance therapy in Platinum-Sensitive, recurrent ovarian cancer ［J］. The New England Journal of Medicine, 2016, 375(22): 2154-2164.
［17］MOORE K, COLOMBO N, SCAMBIA G, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer ［J］. New England Journal of Medicine, 2018, 379(26): 2495-2505.
［18］KAUFMAN B, SHAPIRA-FROMMER R, SCHMUTZLER R K, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation ［J］. Journal of Clinical Oncology, 2015, 33(3): 244-250.
［19］KALLI K R, OBERG A L, KEENEY G L, et al. Folate receptor alpha as a tumor target in epithelial ovarian cancer ［J］. Gynecologic Oncology, 2008, 108(3): 619-626.
［20］PONTE J F, AB O, LANIERI L, et al. Mirvetuximab soravtansine (IMGN853), a folate receptor Alpha-Targeting Antibody-Drug conjugate, potentiates the activity of standard of care therapeutics in ovarian cancer models1 ［J］. Neoplasia, 2016, 18(12): 775-784.
［21］MOORE K N, VERGOTE I, OAKNIN A, et al. FORWARD I: a phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer ［J］. Future Oncology, 2018, 14(17): 1669-1678.
［22］PUJADE-LAURAINE E. New treatments in ovarian cancer ［J］. Annals of Oncology, 2017, 28(8): 57-60.
［23］MATULONIS U A, SHAPIRA-FROMMER R, SANTIN A D, et al. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer:results from the phase 2 KEYNOTE-100 study ［Z］, 2019.
［24］IGCS. 17th Biennial Meeting of the International Gynecologic Cancer Society［C］. Kyoto Japan，2018．
［25］KONSTANTINOPOULOS P A, WAGGONER S, VIDAL G A, et al. Single-Arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent Platinum-Resistant ovarian carcinoma ［Z］, 2019.
［26］PEDERSEN M, WESTERGAARD M C, MILNE K, et al. Adoptive cell therapy with tumor-infiltrating lymphocytes in patients with metastatic ovarian cancer: a pilot study ［J］. Oncoimmunology, 2018, 7(12): e1502905.
［27］KRISTELEIT R, DAVIDENKO I, SHIRINKIN V A, et al. A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)-only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer ［J］. Gynecologic Oncology, 2017, 146(3): 484-490.
［28］SAHIN U, DERHOVANESSIAN E, MILLER M, et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer ［J］. Nature, 2017, 547(7662): 222-226.
［29］SAHIN U, TURECI O. Personalized vaccines for cancer immunotherapy ［J］. Science, 2018, 359(6382, SI): 1355-1360.
相似文献/References:
[1]伍军平,陈宝霞,罗新,等.妊娠晚期胎死宫内合并卵巢癌破裂1例[J].中国计划生育和妇产科,2011,(03):0.
[2]张爱臣,佟玲玲.卵巢癌的诊治进展[J].中国计划生育和妇产科,2013,(01):0.
ZHANG Ai-chen,TONG Ling-ling.[J].Chinese Journal of Family Planning & Gynecotokology,2013,(10):0.
[3]李慧,汤小晗,卢美松*.肝素结合表皮生长因子与卵巢癌顺铂化疗耐药性关系的研究[J].中国计划生育和妇产科,2016,(12):15.
LI Hui,TANG Xiao-han,LU Mei-song*.Study on relationship between HB-EGF and resistance of ovarian cancer to chemotherapy drug[J].Chinese Journal of Family Planning & Gynecotokology,2016,(10):15.
[4]何丽,林永红,李笑晓,等.防己诺林碱联用紫杉醇对耐药卵巢癌SKOV3/ADM细胞作用机制的初步研究[J].中国计划生育和妇产科,2017,(6):59.
HE Li,LIN Yong-hong,LI Xiao-xiao,et al.Effect of fangchinoline combined with paclitaxel on drug resistant ovarian cancer SKOV3 / ADM cells: a preliminary study[J].Chinese Journal of Family Planning & Gynecotokology,2017,(10):59.
[5]卢丹华,洪莉*,杨将,等.Jagged1-STAT 3信号轴对卵巢癌细胞A 2780迁移能力的影响[J].中国计划生育和妇产科,2017,(8):72.
LU Dan-hua,HONG Li*,YANG Jiang,et al.Effect of Jagged1-STAT 3 signal axis on migration ability of ovarian cancer cell A 2780[J].Chinese Journal of Family Planning & Gynecotokology,2017,(10):72.
[6]张雪梅.紫杉醇联合洛铂化疗方案对晚期初治卵巢癌术后
患者早期临床疗效及毒副反应发生率的分析[J].中国计划生育和妇产科,2018,(2):72.
ZHANG Xue-mei.Early clinical efficacy and side effects of paclitaxel combined with
lobaplatin regimen on postoperative patients with advanced ovarian cancer[J].Chinese Journal of Family Planning & Gynecotokology,2018,(10):72.
[7]石亚利,梁华茂*,姚颖.腹腔镜卵巢恶性肿瘤再分期手术临床分析（附38例报道）[J].中国计划生育和妇产科,2018,(3):37.
SHI Ya-li,LIANG Hua-mao*,YAO Ying.Clinical analysis of laparoscopic restaging surgery for ovarian
malignancies (report of 38 cases)[J].Chinese Journal of Family Planning & Gynecotokology,2018,(10):37.
[8]叶海琼,秦明丽,傅晓冬*.卵巢癌程序性细胞凋亡因子4的临床意义及对预后的评估[J].中国计划生育和妇产科,2018,(4):58.
YE Hai-qiong,QIN Ming-li,FU Xiao-dong*.Clinical significance and prognostic value of programmed cell death factor 4 in patients with ovarian cancer[J].Chinese Journal of Family Planning & Gynecotokology,2018,(10):58.
[9]陈彩香*,文锦娣,杨海珍.子宫内膜异位症相关卵巢癌患者临床特点分析[J].中国计划生育和妇产科,2018,(4):62.
CHEN Cai-xiang*,WEN Jin-di,YANG Hai-zhen.Clinical characteristics of patients with endometriosis associated ovarian cancer[J].Chinese Journal of Family Planning & Gynecotokology,2018,(10):62.
[10]范云龙,杨建华.微生物在卵巢癌发病机制与治疗中的作用[J].中国计划生育和妇产科,2018,(5):24.